APEIRON Biologics AG and RENTSCHLER Biotechnologie GmbH have entered a partnership agreement for the manufacture of GMP material for advanced clinical studies, as well as market supply of Apeiron’s lead program APN311. The partnership agreement includes the transfer of the manufacturing process to Rentschler, GMP manufacturing, and process validation in preparation of the MAA/BLA submission as well as future market supply. APN311 is a chimeric antibody that targets the GD2 antigen, which is abu...